Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines. Please watch the video at Investors.com ...
Merck opened a 225,000-square-foot facility dedicated solely to expanding vaccine manufacturing. The Rahway-based research-intensive biopharmaceutical announced the launch of the $1 billion ...
Hosted on MSN2mon
Merck rival Summit draws new buy from Truist on deal prospectsSummit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won a new buy recommendation from Truist on Wednesday based on its deal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback